


PTO-1449 RERODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 21, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1016-029		APPLICATION NO. 10/719,432 Cont. App. of 09/841,179	
	APPLICANT Spiros Jamas <i>et al.</i>			
	FILING DATE	CONFIRMATION NO.	GROUP 1614	

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
mm	AA	4,810,646	03/07/89	Jamas <i>et al.</i>
	AB	4,761,402	08/02/88	Williams <i>et al.</i>
	AC	4,739,046	04/19/88	DiLuzio <i>et al.</i>
	AD	4,138,479	02/06/79	Truscheit <i>et al.</i>
	AE	4,237,266	12/02/80	Sugiura <i>et al.</i>
	AF	4,707,471	11/17/87	Larm <i>et al.</i>
	AG	5,032,401	07/16/91	Jamas <i>et al.</i>
	AH	5,057,503	10/15/91	Czop <i>et al.</i>
	AI	5,322,841	11/02/92	Jamas <i>et al.</i>
	AJ	5,320,849	06/14/94	Hagiwara <i>et al.</i>
	AK	5,488,040	01/30/96	Jamas <i>et al.</i>
	AA2	5,532,223	07/02/96	Jamas <i>et al.</i>
	AB2	5,622,939	04/22/97	Jamas <i>et al.</i>
	AC2	3,943,247	03/09/76	Komatsu <i>et al.</i>
	AD2	5,504,079	04/02/96	Jamas <i>et al.</i>
	AE2	5,401,647	03/28/95	Tanaka <i>et al.</i>
	AF2	5,783,569	7/21/98	Jamas <i>et al.</i>
	AG2	5,817,643	10/06/98	Jamas <i>et al.</i>
	AH2	4,975,421	12/04/90	Williams <i>et al.</i>
	AI2	5,474,984	12/12/95	Tanaka <i>et al.</i>
	AJ2	4,946,450	08/07/90	Erwin
	AK2	4,992,540	02/12/91	Jamas <i>et al.</i>
	AA3	5,663,324	09/02/97	Jamas <i>et al.</i>
	AB3	5,633,369	05/27/97	Jamas <i>et al.</i>
✓	AC3	5,811,542	09/22/98	Jamas <i>et al.</i>

EXAMINER 	DATE CONSIDERED 8-8-01
---	---------------------------

PTO-1449 RERODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 21, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1016-029	APPLICATION NO. 10/719,432 Cont. App. 509/841,179	
	APPLICANT Spiros Jamas <i>et al.</i>		
	FILING DATE	CONFIRMATION NO.	GROUP

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO	
	AL	59210901	06-APR-95	Japan (Abstract)	X	
	AM	59045301	21-JUN-84	Japan (Abstract)	X	
	AN	56076401	11-SEP-81	Japan (Abstract)	X	
	AO	55071701	12-AUG-80	Japan (Abstract)	X	
	AP	20764118	02-DEC-81	Great Britain		
	AQ	91/03495	21-MAR-91	PCT International		
	AL2	WO 94/04163	03-MAR-94	PCT International		
	AM2	WO 91/03248	31-MAR-91	PCT International		
	AN2	0463540	02-JAN-92	EPO		
	AO2	94/03498	17-FEB-94	PCT International		
	AP2	92/13896	20-AUG-92	PCT International		
	AQ2	94/03500	17-FEB-94	PCT International		
	AL3	0416343	13-MAR-91	EPC		
	AM3					
	AN3					
	AO3					
	AP3					
	AO3					
	AL4					
	AM4					
	AN4					
	AO4					
	AP4					
	AQ4					
	AL5					
	AM5					

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 RERODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 21, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1016-029	APPLICATION NO. 10/ 719,432 Cont. App of 09/841,179	
	APPLICANT Spiros Jamas <i>et al.</i>		
	FILING DATE	CONFIRMATION NO.	GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AR	Janusz, M.J., <i>et al.</i> , "Isolation of Soluble Yeast β -Glucans that Inhibit Human Monocyte Phagocytosis Mediated by β -Glucans Receptors," <i>J. Immunol.</i> , 137:3270-3276 (1986).	
AS	Manners, D.J., <i>et al.</i> , "The Structure of a β -(-3)-D-Glucan from Yeast Cell Walls," <i>Biochem. J.</i> , 135:19-30 (1973).	
AT	Fleet, G.H., <i>et al.</i> , "Isolation and Composition of an Alkali-Soluble Glucan from the Cell Walls of <i>Saccharomyces cerevisiae</i> ," <i>J. Gen. Microbio.</i> , 94:180-192 (1976).	
AU	Miyazaki, T., <i>et al.</i> , "Structural Examination of Antitumour, Water-Soluble Glucans from <i>Grifora umbellata</i> by Use of Four Types of Glucanase," <i>Carbohydrate Research</i> , 65:235-243 (1978).	
AV	Reiskind, J.B. and Mullins, J.T., "Molecular Architecture of the Hyphal Wall of <i>Achlya ambisexualis</i> Raper. II. Ultrastructural Analyses and a Proposed Model," <i>Can. J. Microbiol.</i> , 27:1100-1105 (1981).	
AW	Latgé, J.P., <i>et al.</i> , "Composition Chimique et Ultrastructure des Parois des Hyphaux et des Azygospores de <i>Conidiobolus obscurus</i> ," <i>Can. J. Microbiol.</i> , 30:1507-1421 (1984).	
AX	Sherwood, E.R., <i>et al.</i> , "Soluble Glucan and Lymphokine-Activated Killer (LAK) Cells in the Therapy of Experimental Hepatic Metastases," <i>Chemical Abstracts</i> , 108:179752v (1988).	
AY	Hara, C., <i>et al.</i> , "A Branched (1-3)- β -D-Glucan from a Water Extract of <i>Dictyophora indusiata</i> FISCH," <i>Carb. Res.</i> , 145:237-246 (1986).	
AZ	Goldman, R., "Induction of a β -1,3-D-Glucan Receptor in P388D1 Cells Treated with Retinoic Acid of 1,25-dihydroxyvitamin D ₃ ," <i>Immunology</i> , 63:319-324 (1988).	
AR2	Konopski, A., <i>et al.</i> , "Phagocytosis of β -1,3-D-Glucan-Derivatized Microbeads by Mouse Peritoneal Macrophages Involves Three Different Receptors," <i>Scand. J. Immunol.</i> , 33:297-306 (1991).	
AS2	Williams, D.L., <i>et al.</i> , "Development of a Water-Soluble, Sulfated (1-3)- β -D-Glucan Biological Response Modifier Derived from <i>Saccharomyces cerevisiae</i> ," <i>Carbohydrate Research</i> , 235:247-257 (1992).	
AT2	Williams, D.L., <i>et al.</i> , "A Sequential Multi-Assay Protocol for the Preclinical Assessment of Natural Product Complex Carbohydrate Immunomodulators," <i>Develop. Biol. Standard</i> , 77:129-136(1992).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 21, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1016-029	APPLICATION NO. 10/719,432 Cont. App of 09/841,139	
	APPLICANT Spiros Jamas <i>et al.</i>		
	FILING DATE	CONFIRMATION NO.	GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AU2	Williams, D.L., <i>et al.</i> , Development, Physiochemical Characterization and Preclinical Efficacy Evaluation of a Water Soluble Glucan Sulfate Derived from <i>Saccharomyces cerevisiae</i> , "Immunopharmacology, 22:139-156 (1991).	
AV2	Bacon, J., <i>et al.</i> , "The Glucan Components of the Cell Wall of Baker's Yeast (<i>Saccharomyces cerevisiae</i>) Considered in Relation to its Ultrastructure," <i>Biochem. J.</i> , 114:557-567 (1969).	
AW2	Vestnick Federalniho Uradu Pro Vynalezky, 10:111 (1989).	
AX2	Vestnick Federalniho Uradu Pro Vynalezky, 11:122-123 (1989).	
AY2	Onderdonk, A.B., <i>et al.</i> , "Anti-Infective Effect of Poly- β 1-6-Glucotrisyl- β 1-3-Glucopyranose Glucan <i>In Vivo</i> ," <i>Infect. Immun.</i> , 60:1642-1647 (1992).	
AZ2	Abel, G. and Czop, J.K., "Activation of Human Monocyte GM-CSF and TNF- α Production by Particulate Yeast Glucan," International Congress for Infectious Diseases, Montreal Canada (Abstract) July 15-19, 1990.	
AR3	Chihara, G., <i>et al.</i> , "Lentinan as a Host Defense Potentiator (HPD)," <i>Int. J. Immunotherapy</i> , 4:145-154 (1989).	
AS3	Sherwood, E.R., <i>et al.</i> , "Enhancement of Interleukin-1 and Interleukin-2 Production by Soluble Glucan," <i>Int. J. Immunopharm.</i> , 9(3):261-267 (1987).	
AT3	Williams, D.L., <i>et al.</i> , "Pre-clinical Safety Evaluation of Soluble Glucan," <i>Int. J. Immunopharm.</i> , 10(4):405-414 (1988).	
AU3	Browder, W., <i>et al.</i> , "Beneficial Effect of Enhanced Macrophage Function in the Trauma Patient," <i>Ann. Surg.</i> , p. 605-613 (1990).	
AV3	Jamas, <i>et al.</i> , "A Novel Class of Macrophage-Activating Immunomodulators," ACS Symposium Series, <i>Polymeric Drugs and Delivery Systems</i> , Chapter 5, pp. 44-51 (1991).	
AW3	Shiota, M., <i>et al.</i> , "Comparison of β -Glucan Structures in a Cell Wall Mutant of <i>Saccharomyces cerevisiae</i> and the Wild Type," <i>J. Biochem.</i> , 98:1301-1307 (1985).	
AX3	Jamas, <i>et al.</i> , "PGG-A Novel Class of Macrophage Activating Immunomodulators," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990.	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 21, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1016-029		APPLICATION NO. 10/719,432 Cont. App of 09/04/1,190	
	APPLICANT Spiros Jamas <i>et al.</i>			
	FILING DATE	CONFIRMATION NO.	GROUP	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AY3	Katzen, <i>et al.</i> , "PGG, a Glucose Polymer, Primes Interleukin-1 and Tumor Necrosis Factor Production," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990.	
AZ3	Shah, <i>et al.</i> , "Influence of PGG on the Phagocytosis of <i>Staphylococcus aureus</i> or <i>Escherichia coli</i> ," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990.	
AR4	Onderdonk, A.B., "Effect of a New Carbohydrate Polymer on Survival in a Mouse Model for Experimental <i>E. coli</i> Sepsis," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990.	
AS4	Arbo, A. and Santos, J.I., "Effect of PGG on Neutrophil (PMN) Function in Experimental Malnutrition," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990.	
AT4	Onderdonk, A.B., <i>et al.</i> , "Protective Effect of a New Carbohydrate Polymer in a Rat Model for Experimental Intraabdominal Sepsis," First International Congress on Biological Response Modifiers, Quebec, Canada, (Abstract), March, 1991.	
AU4	Lagrange, P.H. and Fourgeaud, M., "Enhanced Natural Resistance Against Severe Disseminated <i>Candida albicans</i> ," <i>Int'l J. Experimental Clin. Chemotherapy</i> , 40(1):48-55 (1991).	
AV4	Sakurai, <i>et al.</i> , "Intravenously Administered (1-3)- β -D-Glucan, SSG, Obtained from <i>Sclerotinia sclerotiorum</i> IFO9395 Augments Murine Peritoneal Macrophage Function <i>In Vivo</i> ," <i>Chem. Pharm. Bull.</i> , 40(8):2120-2124 (1992).	
AW4	Jamas, S., <i>et al.</i> , "PGG-A Novel Class of Macrophage Activating Immunomodulators," <i>Polymer Preprints</i> , 31:194-195 (1990).	
AX4	Sasaki, <i>et al.</i> , "Antitumor Activity of Degraded Products of Lentinan: Its Correlation with Molecular Weight," <i>Gann</i> , 67:191-195 (1976).	
AY4	Di Luzio, <i>et al.</i> , "Comparative Tumor-Inhibitory and Anti-Bacterial Activity of Soluble and Particulate Glucan," <i>Int. J. Cancer</i> , 24:773-779 (1979).	
AZ4	Burgaleta, C. and Golde, D.W., "Effect of Glucan of Granulopoiesis and Macrophage Genesis in Mice," <i>Cancer Research</i> , 37:1739-1742 (1977).	
ARS	Kenyon, A.J., "Delayed Wound Healing in Mice Associated with Viral Alteration of Macrophages," <i>Am. J. Vet. Res.</i> , 44(4):652-656 (1983).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 21, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1016-029	APPLICATION NO. 10179,432 Cont. App. 500/841,179	
	APPLICANT Spiros Jamas <i>et al.</i>		
	FILING DATE	CONFIRMATION NO.	GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AS5	Babineau, T., <i>et al.</i> , "Randomized Phase I/II Trial of a Macrophage-Specific Immunomodulator PGG-Glucan (Betafectin™) in High Risk Surgery Patients," Clinical Congress of the American College of Surgeons, San Francisco, CA, October 11, 1993.	
AT5	Babineau, T., <i>et al.</i> , "Randomized Multicenter Phase I/II Trial of a Macrophage-Specific Immunomodulator (PGG-Glucan) in High Risk Surgery Patients," Surgical Infection Society Meeting, April, 29, 1994.	
AU5	Adachi, Y., <i>et al.</i> , "Enhancement of Cytokine Production by Macrophages Stimulated with (1-3)- β -D-Glucan, Grifolan (GRN), Isolated from <i>Grifola frondosa</i> ," <i>Biol. Pharm. Bull.</i> , 17(12):1554-1560 (1994).	
AV5	Babineau, T.J., <i>et al.</i> , "A Phase II Multicenter, Double-blind, Randomized, Placebo-Controlled Study of Three Dosages of an Immunomodulator (PGG-Glucan) in High Risk Surgical Patients", <i>Archives of Surgery</i> , 129:1204-1210 (1994).	
AW5	Babineau, T.J., <i>et al.</i> , "Randomized Phase I/II Trial of a Macrophage-Specific Immunomodulator (PGG-Glucan) in High Risk Surgical Patients", <i>Annals of Surgery</i> , 220(5):601-609 (1994).	
AX5	Norton, J.A., "Biological Therapy of Sepsis", <i>Annals of Surgery</i> , 220(5):599-600 (1994).	
AY5	"Tumor Necrosis Factor: A Biological Enigma," <i>Science Impact</i> , pp. 5-6, June 1989.	
AZ5	Dinarello, C.A. and Neta, R., "An Overview on Interleukin-1 as a Therapeutic Agent", <i>Biotherapy</i> , 1:245-254 (1989).	
AR6	Van der Meer, J.W.M., <i>et al.</i> , "Concentrations of Immunoreactive Human Tumor Necrosis Factor Alpha Produced by Human Mononuclear Cells In Vitro," <i>Journal of Leukocyte Biology</i> , 43:216-223 (1988).	
AS6	Dinarello, C.A., "Interleukin-1," <i>Reviews of Infectious Diseases</i> , 6(1):51-95 (1984).	
AT6	Duvic, M., <i>et al.</i> , "Glucan-Induced Keratoderma in Acquired Immunodeficiency Syndrome," <i>Arch Dermatol.</i> , 123:751-756	
AU6	Adachi, Y., <i>et al.</i> , "Macrophage Activation in Vitro by Chemically Cross-Linked (1-3)- β -D-Glucans," <i>Chem. Pharm. Bull.</i> , 38(4):988-992 (1990).	
AV6	Sietsma, J.H. and Wessels, J.G.H., "Solubility of (1-3)- β -D-Glucan in Fungal Walls: Importance of Presumed Linkage between Glucan and Chitin", <i>J. Gen. Microbiology</i> , 125:209-212 (1981).	

EXAMINER	DATE CONSIDERED
----------	-----------------